Inovio Pharmaceuticals (INO) Gets a Hold Rating from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals (INOResearch Report). The company’s shares closed last Friday at $10.54.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 18.4% and a 57.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Biospecifics Technologies, and Springworks Therapeutics.

Inovio Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $14.17, which is a 24.3% upside from current levels. In a report issued on November 10, Roth Capital also upgraded the stock to Hold with a $8.00 price target.

See today’s analyst top recommended stocks >>

Inovio Pharmaceuticals’ market cap is currently $1.79B and has a P/E ratio of -7.80. The company has a Price to Book ratio of 5.76.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.